← All peptidesPDA-V1 attestation Citations
verifiedBioGate · GREENGrade B
Bivalirudin (Angiomax)
fPRPGGGGNGDFEEIPEEYLDirect, reversible thrombin inhibitor; binds both catalytic site and exosite I via flexible Gly-linker. Short ~25-min half-life.
D-Phe¹synthetic 20-residue thrombin inhibitor
MW
2180.30
Length
20aa
Posterior
56.5%
Structural preview · ESMFold-2 mockdeterministic per sequence
Backbone preview · D-Phe¹
Cryptographic chain of custody.
- Outer PDA hash
- Inputs hash
- Merkle root
- TEE attestation
- Protocol version
- PDA-V1
- Source
- peptide-md
- Model version
- structure-fm-2026.04
- Candidates emitted
- 5
- Signed
- 2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with
@peptide-md/verifier.Real-world evidence
Cohort-attested outcomes.
Cohorts
6
Participants
65
Mean Δ
+4
Δ HRV ms (8-week) · 95% CI [3.01, 4.98]
IPNFT · Molecule IPNFT V2Solana
Bivalirudin (Angiomax)
8596e3…388296Royalty cascade
12.72%
Holders
117
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
Source literature.
Grade A2006 · N Engl J Med
Bivalirudin during primary PCI in acute myocardial infarction (HORIZONS-AMI)
Stone GW et al.